Influenza and Acute Respiratory Viral Infections Clinical Trial
Official title:
International Multicenter Double-blind Placebo-controlled Randomized Parallel Group Clinical Trial of Efficacy of Anaferon for Children in the Treatment of Influenza and Acute Respiratory Viral Infections in Children
| Verified date | July 2019 |
| Source | Materia Medica Holding |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The purpose of this study is:
• To obtain additional data on therapeutic efficacy of Anaferon for children in the treatment
of influenza and acute respiratory viral infections in children
| Status | Completed |
| Enrollment | 569 |
| Est. completion date | April 16, 2018 |
| Est. primary completion date | April 16, 2018 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 3 Years to 12 Years |
| Eligibility |
Inclusion Criteria: 1. Patients of both sexes aged 3-12 years inclusively. 2. Diagnosis of influenza/ARVI according to physician's examination: body temperature = 38.0°C at the time of examination + symptom score = 4 (at least 1 systemic symptom =2 and 1 nasal/throat/chest symptom =2 or several symptoms = 1 score). 3. The first 24 hours from the beginning of manifestations of influenza/ARVI. 4. The possibility to start therapy within 24 hours from the first symptoms of ARVI. 5. Availability of a patient information sheet (Informed Consent form) for parents/adoptive parents for participation in the study signed by one of the parents/adoptive parents. Exclusion Criteria: 1. Suspected pneumonia, bacterial infection or severe disease requiring antibacterial products (including sulfanilamides) starting from the first day of the disease. 2. Clinical symptoms of severe influenza/ARVI requiring hospitalization. 3. Suspected initial manifestations of the diseases having the symptoms similar to the ones of influenza/ARVI (other infectious diseases, influenza-like syndrome at debut of systemic connective tissue diseases, oncohematological and other diseases). 4. Medical history of primary and secondary immunodeficiencies: ?) lymphoid system immunodeficiencies (?-cell and/or B-cell, immunodeficiencies with predominant antibody deficiency); b) phagocytic deficiencies; c) complement factor deficiency; d) combined immunodeficiencies including AIDS secondary to HIV-infection; toxic, autoimmune, infectious, radiation panleukopenic syndrome; systemic lymphocytopenic syndrome; polyclonal lymphocytic activation syndrome; postsplenectomic syndrome; congenital asplenia; immune complex pathological syndrome associated with infectious, autoimmune and allergic diseases. 5. Medical history of sarcoidosis. 6. Oncology. 7. Exacerbation or decompensation of chronic diseases affecting ability to participate in the clinical study. 8. Medical history of polyvalent allergy. 9. Allergy/intolerance to any of the components of medications used in the treatment. 10. Malabsorption syndrome, including congenital or acquired lactase or other disaccharidase deficiency, galactosemia. 11. Intake of medicines listed in the section "Prohibited concomitant therapy" within 1 month prior to the inclusion in the study. 12. Drug addiction, alcohol consumption at more than 2 alcohol units per day by the subject's parents/adoptive parents. 13. Mental diseases of the subject, parents/adoptive parents. 14. Subjects whose parents/adoptive parents, according to the investigator's point of view, will not follow the observation requirements during the study or study product dosing regimen. 15. Participation in other clinical studies within 3 months prior to the inclusion in the study. 16. Parent/adoptive parent of the subject is related to the investigator team of medical facility directly involved in the study or is a close relative of the investigator. Close relatives include spouse, parents, children or brothers (sisters) regardless of whether they are biological or adoptive ones. 17. Parent/adoptive parent of the subject is working in OOO "NPF "Materia Medica Holding", i.e. is the company official, temporary contract worker or an appointed official responsible for the study or their close relatives. |
| Country | Name | City | State |
|---|---|---|---|
| Belarus | City Child Health Clinical Polyclinic ?13 | Minsk | |
| Belarus | City Child Health Clinical Polyclinic ?17 | Minsk | |
| Belarus | Municipal Health Care Institution "City Child Health Clinical Polyclinic ?10" | Minsk | |
| Russian Federation | Clinic of State Budgetary Institution "Research Institute of nutrition" of the Russian Academy of Medical Sciences | Moscow | |
| Russian Federation | Russian National Research Medical University | Moscow | |
| Russian Federation | Russian National Research Medical University named after N.I. Pirogov | Moscow | |
| Russian Federation | Russian National Research Pirogov Medical University | Moscow | |
| Russian Federation | State Budgetary Educational Institution of Additional Professional Education "Russian Russian Medical Academy of Postgraduate Education" of Ministry of Health of Russian Federation | Moscow | |
| Russian Federation | State Budgetary Institution of Health, "Children's City Hospital ? 9 named after G.N. Speranskii" | Moscow | |
| Russian Federation | State Educational Institution of Higher Professional Education "Moscow State Medical Academy named after I.M. Sechenov" | Moscow | |
| Russian Federation | State Budgetary Educational Institution of Higher Professional Education " Nizhny Novgorod State Medical Academy" of Ministry of Health of Russian Federation | Nizhnij Novgorod | |
| Russian Federation | State Budgetary Educational Institution of Higher Professional Education ''Novosibirsk State Medical University'' of Ministry of Health of Russian Federation | Novosibirsk | |
| Russian Federation | Municipal Health Care Institution "City Child Health Clinical Polyclinic ?5" | Perm | |
| Russian Federation | State Budgetary Educational Institution of Higher Professional Education "Rostov State Medical University" | Rostov-na-Donu | |
| Russian Federation | Co.Ltd "Clinic Allergomed" | St. Petersburg | |
| Russian Federation | St. Petersburg State Budgetary Health Care Institution "?ity Polyclinic ?44" | St. Petersburg | |
| Russian Federation | St. Petersburg State health institution " City Child Health Polyclinic ? 45" | St. Petersburg | |
| Russian Federation | State Budgetary Educational Institution of Higher Professional Education "St. Petersburg State Pediatric Medical Academy" of Ministry of Health of Russian Federation | St. Petersburg | |
| Russian Federation | State Health Care Institution "Child Health City Hospital ?22" | St. Petersburg | |
| Russian Federation | Limited Liability Company "Alliance Biomedical-Russian group" | St.Petersburg | |
| Russian Federation | Bashkir State Medical University of Ministry of Health of Russian Federation | Ufa | |
| Russian Federation | State Budgetary Educational Institution of Higher Professional Education " Yaroslavl State Medical Academy" of Ministry of Health of Russian Federation | Yaroslavl | |
| Russian Federation | State Budgetary Educational Institution of Higher Professional Education "Yaroslavl State Medical Academy | Yaroslavl | |
| Russian Federation | State Budgetary Educational Institution of Higher Professional Education "Yaroslavl State Medical Academy" | Yaroslavl | |
| Russian Federation | Yaroslavl State Medical Academy | Yaroslavl | |
| Ukraine | Vinnytsya M.I. Pyrogov National Medical University | Vinnytsya | |
| Ukraine | Public institution "Zaporizhzhya city multidisciplinary children's hospital ?5" | Zaporozh'ye |
| Lead Sponsor | Collaborator |
|---|---|
| Materia Medica Holding |
Belarus, Russian Federation, Ukraine,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Average Illness Duration | Disease duration is assessed until recovery or significant improvement. Average illness duration is defined as the interval between the start of the trial treatment and the start of the first 24-hour period in which the non-specific symptoms and nasal/ throat/ chest symptoms improve to "absent" or "mild" (Total Symptom Score of severity had decreased to =2 points) and body temperature returns to 37.2°C or below. Based on patient diary data. |
From the time of randomization until the time of recovery/improvement (days 1-14) | |
| Secondary | Percentage of Patients With Recovery/Improvement in Health | Based on Days 2, 3, 4 and 5 of observation treatment (according to the patient's diary), on days 3 and 5 of therapy (according to physician's objective examination). | on days 2, 3, 4 and 5 of the treatment | |
| Secondary | Changes in Body Temperature | Changes in Body Temperature Based on Patient Diary Data | baseline and days 2, 3, 4 and 5 of observation treatment | |
| Secondary | Percentage of Patients With Normal Body Temperature (=37.0º?) | Based on the patient diary data. Axillary temperature (morning and evening) decline to or below 37.0 º?. | on days 2, 3, 4 and 5 of observation treatment | |
| Secondary | Severity of Clinical Manifestations of Influenza / Acute Respiratory Viral Infection by Total Symptom Score. | Total Symptom Score is based on the severity of each Influenza / Acute Respiratory Viral Infection symptom. Total Symptom Score includes 13 symptoms: body temperature, non-specific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness), nasal/throat/chest symptoms. The severity of non-specific and nasal/throat/chest symptom is scored on a symptom severity scale (0=no symptoms; 1=mild symptoms; 2=moderate symptoms; 3=severe symptoms). Minimum score=0; maximum score=39. The severity of symptoms is recorded by the doctors on the case record form on days 3, 5 and by parents/adopter on a diary card twice a day on days 2-6. |
on days 2-6 of observation treatment | |
| Secondary | Assessment of the Severity of Influenza Virus / Acute Respiratory Viral Infection Using the "Area Under the Curve" for an Overall Symptom Assessment | Total Symptom Score is based on the severity of each disease symptom. The TSS includes 13 symptoms: body temperature/fever, non-specific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness), nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, sore throat, hoarseness, cough, chest pain/tightness of the chest). Minimum score=0; maximum score=39. The area under the curve 1 = on days 1, 3, 5 and 7 on the results of doctor`s examination The area under the curve 2 = based on days 1-7 on the patient diary data |
on days 1-7 of observation (based on days 1-7 on the patient diary data; on days 1, 3, 5 and 7 of observation - according to physician's objective examination) | |
| Secondary | Number of Intakes of Antipyretics | Number of Intakes of Antipyretics based on patient diary data | on days 1-5 of therapy | |
| Secondary | Change in Viral Load During the Treatment and Follow-up Periods | Viral load is evaluated in subjects with positive influenza A and B tests. Virus load [log10 copies influenza ?/? RNA per 1 mL] in nasal and pharyngeal swabs is determined using real-time PCR on days 1, 3, 5 and 7. | on days 1, 3, 5, 7 of observation treatment | |
| Secondary | Percentage of Patients With Exacerbation of the Disease Course | The development of disease complications requiring antibiotics drugs or hospitalization | 14 days of observation treatment |